Index -
P/E -
EPS (ttm) -
Insider Own 53.70%
Shs Outstand 31.85M
Perf Week -3.59%
Market Cap 726.18M
Forward P/E -
EPS next Y -
Insider Trans 98.80%
Shs Float 14.75M
Perf Month -
Income -
PEG -
EPS next Q -
Inst Own -
Short Float -
Perf Quarter -
Sales -
P/S -
EPS this Y -
Inst Trans -
Short Ratio -
Perf Half Y -
Book/sh -3.07
P/B -
EPS next Y -
ROA -
Short Interest -
Perf Year -
Cash/sh 1.74
P/C 13.14
EPS next 5Y -
ROE -
52W Range 20.29 - 26.08
Perf YTD -3.59%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -
52W High -12.58%
Beta -
Dividend TTM -
Quick Ratio 7.17
Sales past 5Y 0.00%
Gross Margin -
52W Low 12.40%
ATR (14) 2.78
Dividend Ex-Date -
Current Ratio 7.17
EPS Y/Y TTM -
Oper. Margin -
RSI (14) -
Volatility - -
Employees -
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom -
Target Price -
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q -
Payout -
Rel Volume 0.77
Prev Close 21.23
Sales Surprise -
EPS Surprise -
Sales Q/Q -
Earnings -
Avg Volume 469.70K
Price 22.80
SMA20 4.56%
SMA50 4.56%
SMA200 4.56%
Trades
Volume 237,753
Change 7.40%
Sep-18-24 03:19AM
Sep-16-24 04:05PM
Sep-12-24 07:11PM
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mathers Edward T Director Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:28 PM BASKETT FOREST 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:26 PM Behbahani Ali 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:24 PM Chang Carmen 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:23 PM Florence Anthony A. Jr. 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:21 PM Makhzoumi Mohamad 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:20 PM Walker Paul Edward 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:18 PM Yang Rick 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:17 PM SANDELL SCOTT D 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:14 PM ORBIMED ADVISORS LLC Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:13 PM New Enterprise Associates 17, 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:12 PM Frazier Life Sciences X, L.P. 10% Owner Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:11 PM Heron Patrick J Director Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:09 PM Aynechi Tiba Director Sep 16 '24 Buy 16.00 750,000 12,000,000 2,136,335 Sep 17 08:05 PM GORDON CARL L Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:05 PM
Index RUT
P/E -
EPS (ttm) -25.49
Insider Own 36.37%
Shs Outstand 8.02M
Perf Week -14.36%
Market Cap 329.96M
Forward P/E -
EPS next Y -9.79
Insider Trans 5.57%
Shs Float 5.92M
Perf Month -22.90%
Income -92.22M
PEG -
EPS next Q -2.55
Inst Own 62.88%
Short Float 4.86%
Perf Quarter 0.28%
Sales 0.00M
P/S -
EPS this Y 82.24%
Inst Trans -28.19%
Short Ratio 3.31
Perf Half Y -45.42%
Book/sh 21.34
P/B 1.66
EPS next Y -3.86%
ROA -56.06%
Short Interest 0.29M
Perf Year 259.29%
Cash/sh 17.12
P/C 2.07
EPS next 5Y -
ROE -75.75%
52W Range 4.57 - 97.91
Perf YTD -25.98%
Dividend Est. -
P/FCF -
EPS past 5Y -11.67%
ROI -39.06%
52W High -63.76%
Beta 3.85
Dividend TTM -
Quick Ratio 13.28
Sales past 5Y -26.84%
Gross Margin -
52W Low 675.52%
ATR (14) 4.18
Dividend Ex-Date -
Current Ratio 13.28
EPS Y/Y TTM 73.20%
Oper. Margin 0.00%
RSI (14) 37.35
Volatility 9.81% 10.12%
Employees 101
Debt/Eq 0.19
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 123.75
Option/Short No / Yes
LT Debt/Eq 0.19
EPS Q/Q 83.89%
Payout -
Rel Volume 0.74
Prev Close 38.50
Sales Surprise -
EPS Surprise -0.06%
Sales Q/Q -
Earnings Aug 13 AMC
Avg Volume 86.90K
Price 35.48
SMA20 -17.49%
SMA50 -18.80%
SMA200 -30.74%
Trades
Volume 41,912
Change -7.84%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-14-24 Initiated
William Blair
Outperform
$180
Mar-28-24 Reiterated
H.C. Wainwright
Buy
$100 → $115
Feb-27-24 Initiated
BMO Capital Markets
Outperform
$120
Dec-04-23 Initiated
H.C. Wainwright
Buy
$100
Nov-29-23 Initiated
RBC Capital Mkts
Outperform
$70
Nov-10-23 Initiated
Piper Sandler
Overweight
$180
Feb-15-23 Downgrade
Chardan Capital Markets
Buy → Neutral
Feb-13-23 Downgrade
Cowen
Outperform → Market Perform
Sep-22-21 Downgrade
Goldman
Buy → Neutral
$12 → $9
Jan-27-21 Upgrade
JP Morgan
Neutral → Overweight
$56
Dec-22-20 Initiated
B. Riley Securities
Buy
$79
Jul-14-20 Initiated
Oppenheimer
Outperform
$36
May-18-20 Downgrade
JP Morgan
Overweight → Neutral
$27
Oct-28-19 Initiated
JP Morgan
Overweight
$25
Oct-28-19 Initiated
Goldman
Buy
$30
Oct-28-19 Initiated
Cowen
Outperform
Show Previous Ratings
Sep-16-24 08:00AM
Sep-10-24 08:00AM
Aug-28-24 08:00AM
Aug-27-24 08:00AM
Aug-13-24 04:01PM
08:00AM
Loading…
Jul-01-24 08:00AM
Jun-25-24 12:53PM
May-30-24 04:01PM
May-20-24 02:30PM
May-14-24 10:55PM
04:01PM
Apr-18-24 08:30AM
Apr-01-24 04:01PM
Mar-26-24 04:01PM
Feb-27-24 09:55AM
08:00AM
Loading…
08:00AM
Feb-09-24 09:55AM
Jan-18-24 08:00AM
Jan-04-24 08:00AM
Dec-07-23 08:00AM
Nov-28-23 08:00AM
Nov-03-23 03:31PM
12:19PM
Aug-10-23 04:01PM
Jul-17-23 11:59AM
Jul-14-23 11:22AM
06:30AM
May-12-23 04:01PM
Mar-10-23 07:30AM
Feb-27-23 07:30AM
01:55PM
Loading…
Feb-13-23 01:55PM
(American City Business Journals) -80.54%
11:17AM
08:05AM
Dec-19-22 07:30AM
Dec-15-22 07:30AM
Nov-17-22 07:30AM
Nov-08-22 04:05PM
Oct-12-22 07:30AM
Aug-30-22 07:30AM
Aug-09-22 04:05PM
(Business Wire) -11.11%
+9.00%
Jun-24-22 09:03AM
May-25-22 12:00PM
May-18-22 07:30AM
May-04-22 04:30PM
Apr-22-22 07:30AM
Apr-08-22 05:00PM
Mar-15-22 07:30AM
Mar-10-22 06:35PM
Feb-28-22 07:30AM
Jan-14-22 05:43AM
Jan-04-22 07:30AM
Dec-28-21 02:38AM
Dec-09-21 01:18PM
07:30AM
Nov-30-21 05:53AM
Nov-15-21 12:25PM
07:30AM
Nov-09-21 07:30AM
Nov-08-21 03:00PM
Oct-27-21 07:30AM
Oct-21-21 07:30AM
Oct-01-21 08:23AM
Sep-22-21 11:18AM
07:30AM
Sep-08-21 07:30AM
Aug-30-21 05:10PM
Aug-12-21 04:06PM
08:45AM
07:30AM
Aug-04-21 03:00PM
Aug-02-21 03:05PM
02:30PM
12:30PM
12:30PM
11:00AM
10:00AM
09:16AM
09:09AM
05:50AM
03:27AM
Aug-01-21 10:38AM
06:36AM
Jul-30-21 08:49PM
07:19PM
07:10PM
05:15PM
02:57PM
01:30PM
12:40PM
11:30AM
11:30AM
11:00AM
10:00AM
10:00AM
09:30AM
09:00AM
05:18AM
Jul-29-21 08:47PM
05:29PM
04:02PM
Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Colletti Steve Former Officer Aug 30 '24 Proposed Sale 49.24 10,303 507,326 Aug 30 05:28 PM New Enterprise Associates 17, 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM BASKETT FOREST 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Florence Anthony A. Jr. 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Walker Paul Edward 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Chang Carmen 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Mathers Edward T 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Yang Rick 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Makhzoumi Mohamad 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM SANDELL SCOTT D 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Atlas Venture Opportunity Fund 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 195,074 Apr 23 05:23 PM Lucchino David L. Director Nov 22 '23 Sale 37.69 1,156 43,573 22,150 Nov 27 08:48 PM Lucchino David L. Director Nov 10 '23 Sale 41.97 968 40,632 23,306 Nov 22 04:05 PM
Index -
P/E -
EPS (ttm) -0.30
Insider Own 12.71%
Shs Outstand 341.70M
Perf Week 4.92%
Market Cap 28.17B
Forward P/E 97.91
EPS next Y 0.84
Insider Trans -4.15%
Shs Float 298.28M
Perf Month 0.10%
Income -102.02M
PEG -
EPS next Q 0.18
Inst Own 75.54%
Short Float 3.17%
Perf Quarter 5.79%
Sales 1.48B
P/S 19.07
EPS this Y 44.96%
Inst Trans -0.16%
Short Ratio 3.89
Perf Half Y -14.47%
Book/sh 2.58
P/B 31.95
EPS next Y 18.55%
ROA -3.74%
Short Interest 9.45M
Perf Year 37.40%
Cash/sh 5.15
P/C 16.02
EPS next 5Y -
ROE -13.39%
52W Range 53.88 - 116.00
Perf YTD -0.97%
Dividend Est. -
P/FCF 176.68
EPS past 5Y -13.56%
ROI -4.48%
52W High -28.92%
Beta 1.10
Dividend TTM -
Quick Ratio 3.51
Sales past 5Y 46.59%
Gross Margin 77.26%
52W Low 53.03%
ATR (14) 2.80
Dividend Ex-Date -
Current Ratio 3.51
EPS Y/Y TTM 54.85%
Oper. Margin -11.58%
RSI (14) 58.26
Volatility 3.47% 3.25%
Employees 3682
Debt/Eq 1.63
Sales Y/Y TTM 31.09%
Profit Margin -6.90%
Recom 2.43
Target Price 91.36
Option/Short Yes / Yes
LT Debt/Eq 1.59
EPS Q/Q 84.42%
Payout -
Rel Volume 0.44
Prev Close 82.83
Sales Surprise 1.75%
EPS Surprise 42.05%
Sales Q/Q 29.99%
Earnings Aug 01 AMC
Avg Volume 2.43M
Price 82.45
SMA20 3.80%
SMA50 3.78%
SMA200 -1.40%
Trades
Volume 701,130
Change -0.45%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-16-24 Initiated
Wolfe Research
Peer Perform
Jul-08-24 Initiated
Scotiabank
Sector Perform
$85
Jun-25-24 Upgrade
UBS
Sell → Neutral
$76 → $82
May-07-24 Upgrade
DZ Bank
Hold → Buy
$95
Feb-13-24 Downgrade
DZ Bank
Buy → Hold
$110
Feb-09-24 Resumed
Cantor Fitzgerald
Neutral
$100
Jan-18-24 Initiated
Bernstein
Mkt Perform
$85
Jan-17-24 Initiated
CapitalOne
Equal Weight
$83
Dec-15-23 Initiated
Susquehanna
Neutral
$75
Nov-21-23 Upgrade
Oppenheimer
Perform → Outperform
Sep-07-23 Initiated
BofA Securities
Underperform
$52
Aug-07-23 Downgrade
Guggenheim
Neutral → Sell
$50
Jun-05-23 Initiated
UBS
Sell
$55
May-05-23 Upgrade
Guggenheim
Sell → Neutral
Apr-19-23 Resumed
William Blair
Outperform
Feb-14-23 Initiated
Goldman
Sell
$51
Feb-07-23 Initiated
Loop Capital
Hold
$52
Jan-17-23 Downgrade
Guggenheim
Neutral → Sell
$36
Nov-28-22 Resumed
JP Morgan
Neutral
$42
Nov-02-22 Initiated
Macquarie
Neutral
$60
Show Previous Ratings
Sep-19-24 02:02PM
Sep-18-24 09:43PM
05:00PM
(Associated Press Finance)
Sep-13-24 05:50PM
04:15AM
05:56PM
Loading…
Sep-11-24 05:56PM
09:00AM
03:37AM
Sep-05-24 02:52PM
Sep-03-24 05:45AM
Aug-30-24 05:25AM
Aug-28-24 09:00AM
05:12AM
Aug-23-24 09:05AM
Aug-16-24 09:00AM
06:30AM
Loading…
Aug-14-24 06:30AM
Aug-13-24 12:50PM
Aug-12-24 09:45AM
Aug-07-24 03:16AM
Aug-06-24 06:31AM
Aug-05-24 09:00AM
Aug-03-24 01:04AM
Aug-02-24 03:42PM
(Yahoo Finance Video) +6.80%
11:54AM
08:48AM
08:19AM
07:20AM
12:45AM
Aug-01-24 06:00PM
05:38PM
(Investor's Business Daily)
04:56PM
Loading…
04:56PM
(Associated Press Finance)
04:43PM
04:28PM
04:15PM
Jul-31-24 03:05AM
Jul-30-24 02:37PM
Jul-29-24 12:16PM
08:49AM
Jul-26-24 05:50PM
Jul-22-24 06:00PM
Jul-21-24 11:55PM
Jul-19-24 04:13PM
(The Wall Street Journal)
Jul-17-24 09:27AM
Jul-16-24 06:00PM
Jul-15-24 10:00AM
Jul-14-24 05:19AM
Jul-13-24 08:00AM
Jul-10-24 06:00PM
Jul-09-24 04:15PM
03:22PM
10:15AM
06:42AM
Jul-08-24 04:45PM
Jul-03-24 05:11PM
05:15AM
Jul-01-24 11:42AM
Jun-30-24 01:00PM
Jun-28-24 05:50PM
12:15PM
07:33AM
Jun-27-24 09:54AM
09:45AM
Jun-25-24 09:00AM
07:59AM
Jun-24-24 06:00PM
09:00AM
Jun-22-24 06:36AM
Jun-21-24 12:26PM
Jun-20-24 01:01PM
Jun-18-24 06:00PM
04:00AM
Jun-11-24 09:00AM
Jun-08-24 12:44PM
Jun-07-24 05:50PM
Jun-06-24 06:19AM
06:00AM
Jun-04-24 09:23AM
Jun-03-24 11:54AM
May-31-24 11:04AM
May-30-24 05:17PM
09:00AM
08:00AM
May-29-24 09:00AM
May-28-24 08:35AM
May-26-24 05:35AM
May-24-24 06:45AM
May-16-24 06:45AM
May-15-24 08:00AM
(Investor's Business Daily)
May-14-24 09:00AM
May-09-24 04:52PM
01:31PM
05:30AM
May-08-24 06:16AM
May-07-24 09:35AM
09:00AM
07:52AM
May-06-24 05:15PM
04:39PM
09:00AM
07:07AM
Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration and Cloudflare marketplace. It operates through United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
SEIFERT THOMAS J CHIEF FINANCIAL OFFICER Sep 18 '24 Sale 78.36 15,000 1,175,378 281,403 Sep 19 05:13 PM THOMAS J SEIFERT Officer Sep 18 '24 Proposed Sale 79.11 15,000 1,186,650 Sep 18 04:45 PM Zatlyn Michelle President and COO Sep 09 '24 Sale 77.13 12,820 988,780 0 Sep 11 07:55 PM Zatlyn Michelle President and COO Sep 11 '24 Sale 76.14 12,820 976,168 0 Sep 11 07:55 PM Zatlyn Michelle President and COO Sep 10 '24 Sale 75.63 12,820 969,517 0 Sep 11 07:55 PM Prince Matthew CEO & Chair of the Board Sep 05 '24 Sale 78.51 52,384 4,112,554 10,761 Sep 06 09:03 PM Prince Matthew CEO & Chair of the Board Sep 04 '24 Sale 78.06 52,384 4,089,133 10,761 Sep 06 09:03 PM Prince Matthew CEO & Chair of the Board Sep 06 '24 Sale 76.55 52,384 4,009,768 10,761 Sep 06 09:03 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER Sep 04 '24 Sale 78.05 15,000 1,170,818 281,403 Sep 05 04:35 PM Kramer Douglas James CHIEF LEGAL OFFICER Sep 03 '24 Sale 81.53 3,000 244,590 185,386 Sep 04 04:26 PM THOMAS J SEIFERT Officer Sep 04 '24 Proposed Sale 78.11 15,000 1,171,650 Sep 04 04:14 PM DOUGLAS KRAMER Officer Sep 03 '24 Proposed Sale 81.53 3,000 244,590 Sep 03 04:15 PM Zatlyn Michelle President and COO Aug 20 '24 Sale 83.74 35,117 2,940,717 0 Aug 22 07:23 PM Zatlyn Michelle President and COO Aug 22 '24 Sale 81.91 25,640 2,100,243 0 Aug 22 07:23 PM Zatlyn Michelle President and COO Aug 21 '24 Sale 81.74 25,640 2,095,826 0 Aug 22 07:23 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER Aug 20 '24 Sale 82.84 28,636 2,372,117 281,403 Aug 22 04:12 PM Michelle Zatlyn Officer Aug 20 '24 Proposed Sale 82.38 240,237 19,790,724 Aug 20 04:46 PM THOMAS J SEIFERT Officer Aug 20 '24 Proposed Sale 84.07 28,636 2,407,429 Aug 20 04:29 PM Riley Janel CHIEF ACCOUNTING OFFICER May 29 '24 Sale 73.47 17,938 1,317,982 87,270 Aug 16 05:19 PM Riley Janel CHIEF ACCOUNTING OFFICER Aug 16 '24 Sale 81.65 3,495 285,375 80,183 Aug 16 05:19 PM Prince Matthew CEO & Chair of the Board Aug 07 '24 Sale 78.17 52,384 4,094,614 0 Aug 09 07:05 PM Prince Matthew CEO & Chair of the Board Aug 09 '24 Sale 77.86 52,384 4,078,387 0 Aug 09 07:05 PM Prince Matthew CEO & Chair of the Board Aug 08 '24 Sale 76.70 52,384 4,017,884 0 Aug 09 07:05 PM Matthew Prince Officer Aug 07 '24 Proposed Sale 76.37 471,456 36,005,095 Aug 07 05:12 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER Aug 02 '24 Sale 78.71 15,000 1,180,714 309,937 Aug 05 05:30 PM THOMAS J SEIFERT Officer Aug 02 '24 Proposed Sale 74.40 15,000 1,116,000 Aug 02 04:21 PM Kramer Douglas James CHIEF LEGAL OFFICER Aug 01 '24 Sale 77.17 3,000 231,510 195,303 Aug 02 04:16 PM Eitel Maria S Director Aug 01 '24 Sale 77.68 6,875 534,016 12,802 Aug 02 04:07 PM DOUGLAS KRAMER Officer Aug 01 '24 Proposed Sale 77.17 3,000 231,510 Aug 01 04:25 PM MARIA EITEL Director Aug 01 '24 Proposed Sale 77.68 6,875 534,016 Aug 01 04:16 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER Jul 18 '24 Sale 78.89 15,000 1,183,382 309,937 Jul 19 05:35 PM Prince Matthew CEO & Chair of the Board Jul 09 '24 Sale 82.96 52,384 4,345,580 8,742 Jul 11 07:09 PM Prince Matthew CEO & Chair of the Board Jul 11 '24 Sale 82.67 52,384 4,330,796 8,742 Jul 11 07:09 PM Prince Matthew CEO & Chair of the Board Jul 10 '24 Sale 81.36 52,384 4,262,027 8,742 Jul 11 07:09 PM Zatlyn Michelle President and COO Jul 01 '24 Sale 82.52 102,580 8,464,511 0 Jul 03 05:45 PM Zatlyn Michelle President and COO Jul 03 '24 Sale 85.28 25,640 2,186,550 0 Jul 03 05:45 PM Zatlyn Michelle President and COO Jul 02 '24 Sale 84.49 25,640 2,166,370 0 Jul 03 05:45 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER Jul 03 '24 Sale 84.97 15,000 1,274,571 309,937 Jul 03 04:57 PM Kramer Douglas James CHIEF LEGAL OFFICER Jul 01 '24 Sale 82.65 3,000 247,950 195,303 Jul 02 04:28 PM Ledbetter Carl Director Jun 26 '24 Sale 79.89 8,030 641,500 1,084,364 Jun 26 06:04 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER Jun 20 '24 Sale 78.47 15,000 1,176,991 309,937 Jun 24 04:18 PM Zatlyn Michelle President and COO Jun 20 '24 Sale 78.51 12,820 1,006,444 0 Jun 21 07:10 PM Zatlyn Michelle President and COO Jun 18 '24 Sale 77.54 12,820 994,120 0 Jun 21 07:10 PM Zatlyn Michelle President and COO Jun 21 '24 Sale 76.41 12,820 979,573 0 Jun 21 07:10 PM Ledbetter Carl Director Jun 20 '24 Sale 78.56 10,015 786,785 1,092,394 Jun 20 04:26 PM Prince Matthew CEO & Chair of the Board Jun 12 '24 Sale 75.07 52,384 3,932,231 8,742 Jun 13 08:08 PM Prince Matthew CEO & Chair of the Board Jun 13 '24 Sale 74.46 52,384 3,900,705 8,742 Jun 13 08:08 PM Prince Matthew CEO & Chair of the Board Jun 11 '24 Sale 72.04 52,384 3,773,618 8,742 Jun 13 08:08 PM Ledbetter Carl Director Jun 12 '24 Sale 74.48 7,986 594,781 1,102,409 Jun 13 04:13 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER Jun 05 '24 Sale 69.12 15,000 1,036,794 309,937 Jun 06 04:09 PM Suder Katrin Director Jun 04 '24 Sale 67.11 574 38,521 51,162 Jun 05 05:15 PM Ledbetter Carl Director Jun 05 '24 Sale 68.65 30,270 2,077,911 1,110,395 Jun 05 05:13 PM Kramer Douglas James CHIEF LEGAL OFFICER Jun 03 '24 Sale 68.77 3,000 206,310 195,303 Jun 04 04:28 PM Ledbetter Carl Director May 29 '24 Sale 72.79 7,994 581,848 1,140,665 May 29 04:13 PM Ledbetter Carl Director May 22 '24 Sale 73.84 9,999 738,364 1,148,659 May 23 04:21 PM Zatlyn Michelle President and COO May 20 '24 Sale 74.94 60,863 4,560,938 0 May 22 07:50 PM Zatlyn Michelle President and COO May 21 '24 Sale 74.46 12,820 954,538 0 May 22 07:50 PM Zatlyn Michelle President and COO May 22 '24 Sale 74.08 12,820 949,744 0 May 22 07:50 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER May 20 '24 Sale 75.13 28,634 2,151,359 309,937 May 21 04:59 PM Ledbetter Carl Director May 15 '24 Sale 74.56 7,990 595,766 1,158,658 May 16 04:19 PM Ledbetter Carl Director May 08 '24 Sale 72.86 30,145 2,196,419 1,166,648 May 09 04:29 PM Prince Matthew CEO & Chair of the Board May 06 '24 Sale 74.67 52,384 3,911,545 0 May 08 06:54 PM Prince Matthew CEO & Chair of the Board May 07 '24 Sale 74.14 52,384 3,883,938 0 May 08 06:54 PM Prince Matthew CEO & Chair of the Board May 08 '24 Sale 72.51 52,384 3,798,564 0 May 08 06:54 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER May 03 '24 Sale 73.97 15,000 1,109,476 338,469 May 06 04:17 PM Kramer Douglas James CHIEF LEGAL OFFICER May 01 '24 Sale 88.12 3,000 264,360 205,238 May 03 05:39 PM Ledbetter Carl Director May 01 '24 Sale 87.49 8,022 701,860 1,196,793 May 02 04:51 PM Eitel Maria S Director May 01 '24 Sale 88.12 6,875 605,825 16,638 May 02 04:48 PM Ledbetter Carl Director Apr 24 '24 Sale 89.16 10,015 892,960 1,204,815 Apr 25 04:49 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER Apr 18 '24 Sale 87.02 15,000 1,305,249 338,469 Apr 19 05:18 PM Zatlyn Michelle President and COO Apr 16 '24 Sale 89.69 25,640 2,299,578 19,615 Apr 18 08:14 PM Zatlyn Michelle President and COO Apr 17 '24 Sale 90.10 19,505 1,757,371 19,615 Apr 18 08:14 PM Zatlyn Michelle President and COO Apr 18 '24 Sale 87.07 18,955 1,650,463 19,615 Apr 18 08:14 PM Ledbetter Carl Director Apr 17 '24 Sale 90.39 8,029 725,769 1,214,830 Apr 18 06:46 PM Prince Matthew CEO & Chair of the Board Apr 09 '24 Sale 96.04 52,384 5,030,854 0 Apr 11 08:22 PM Prince Matthew CEO & Chair of the Board Apr 11 '24 Sale 95.29 52,384 4,991,826 0 Apr 11 08:22 PM Prince Matthew CEO & Chair of the Board Apr 10 '24 Sale 94.94 52,384 4,973,089 0 Apr 11 08:22 PM Ledbetter Carl Director Apr 10 '24 Sale 94.37 44,154 4,166,635 1,222,859 Apr 11 06:42 PM Ledbetter Carl Director Apr 03 '24 Sale 94.05 7,991 751,566 1,267,013 Apr 04 03:35 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER Apr 03 '24 Sale 94.91 15,000 1,423,642 338,469 Apr 04 03:31 PM Kramer Douglas James CHIEF LEGAL OFFICER Apr 01 '24 Sale 97.16 3,000 291,480 205,238 Apr 02 04:59 PM Ledbetter Carl Director Mar 27 '24 Sale 100.16 9,993 1,000,916 1,275,004 Mar 28 04:06 PM Ledbetter Carl Director Mar 20 '24 Sale 95.08 7,968 757,605 1,284,997 Mar 20 06:59 PM SEIFERT THOMAS J Chief Financial Officer Mar 15 '24 Sale 91.77 95,000 8,718,453 0 Mar 19 04:10 PM SEIFERT THOMAS J Chief Financial Officer Mar 15 '24 Sale 91.77 15,000 1,376,562 338,469 Mar 19 04:10 PM Prince Matthew CEO & Chair of the Board Mar 13 '24 Sale 96.83 52,384 5,072,501 12,183 Mar 14 08:11 PM Prince Matthew CEO & Chair of the Board Mar 12 '24 Sale 96.66 52,384 5,063,274 12,183 Mar 14 08:11 PM Prince Matthew CEO & Chair of the Board Mar 14 '24 Sale 94.25 52,384 4,937,165 12,183 Mar 14 08:11 PM Ledbetter Carl Director Mar 13 '24 Sale 96.43 44,099 4,252,598 1,292,965 Mar 14 04:29 PM Zatlyn Michelle President and COO Mar 08 '24 Sale 101.02 25,640 2,590,144 19,615 Mar 08 07:20 PM Zatlyn Michelle President and COO Mar 07 '24 Sale 98.72 25,640 2,531,290 19,615 Mar 08 07:20 PM Zatlyn Michelle President and COO Mar 06 '24 Sale 97.96 25,640 2,511,730 19,615 Mar 08 07:20 PM Ledbetter Carl Director Mar 06 '24 Sale 98.35 8,022 788,947 1,337,064 Mar 07 06:14 PM Kramer Douglas James CHIEF LEGAL OFFICER Mar 04 '24 Sale 99.64 3,000 298,920 205,238 Mar 05 06:15 PM SEIFERT THOMAS J CHIEF FINANCIAL OFFICER Mar 04 '24 Sale 99.87 15,000 1,498,088 338,469 Mar 05 06:12 PM Eitel Maria S Director Feb 29 '24 Sale 98.51 6,875 677,248 23,513 Feb 29 05:56 PM Ledbetter Carl Director Feb 28 '24 Sale 96.35 10,010 964,484 1,345,086 Feb 29 05:19 PM Prince Matthew CEO & Chair of the Board Feb 22 '24 Sale 99.17 52,384 5,194,859 12,183 Feb 23 08:19 PM Prince Matthew CEO & Chair of the Board Feb 23 '24 Sale 98.75 52,384 5,173,032 12,183 Feb 23 08:19 PM Prince Matthew CEO & Chair of the Board Feb 21 '24 Sale 94.59 52,384 4,955,066 12,183 Feb 23 08:19 PM
Index RUT
P/E -
EPS (ttm) -0.42
Insider Own 44.31%
Shs Outstand 138.14M
Perf Week 8.45%
Market Cap 749.75M
Forward P/E -
EPS next Y -0.43
Insider Trans 0.00%
Shs Float 91.67M
Perf Month 1.67%
Income -75.29M
PEG -
EPS next Q -0.11
Inst Own 51.05%
Short Float 10.27%
Perf Quarter 17.40%
Sales 0.00M
P/S -
EPS this Y -35.06%
Inst Trans 2.44%
Short Ratio 5.34
Perf Half Y -6.85%
Book/sh 0.74
P/B 6.19
EPS next Y 3.85%
ROA -58.02%
Short Interest 9.41M
Perf Year 20.82%
Cash/sh 0.74
P/C 6.17
EPS next 5Y -
ROE -79.48%
52W Range 3.12 - 5.70
Perf YTD -3.09%
Dividend Est. -
P/FCF -
EPS past 5Y 29.09%
ROI -58.72%
52W High -20.09%
Beta 0.96
Dividend TTM -
Quick Ratio 11.29
Sales past 5Y -20.00%
Gross Margin -
52W Low 46.23%
ATR (14) 0.22
Dividend Ex-Date -
Current Ratio 11.29
EPS Y/Y TTM -51.68%
Oper. Margin 0.00%
RSI (14) 56.72
Volatility 5.14% 4.97%
Employees 37
Debt/Eq 0.26
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 10.79
Option/Short Yes / Yes
LT Debt/Eq 0.26
EPS Q/Q -62.62%
Payout -
Rel Volume 0.63
Prev Close 4.64
Sales Surprise -
EPS Surprise -15.05%
Sales Q/Q -
Earnings Aug 12 AMC
Avg Volume 1.76M
Price 4.55
SMA20 4.76%
SMA50 3.36%
SMA200 -0.04%
Trades
Volume 725,535
Change -1.83%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
JMP Securities
Mkt Outperform
$8
Nov-07-23 Initiated
Guggenheim
Buy
$7
May-16-23 Upgrade
Jefferies
Hold → Buy
$2 → $4
Mar-31-23 Downgrade
Jefferies
Buy → Hold
$2
Mar-16-21 Initiated
Piper Sandler
Overweight
$7
Mar-15-21 Initiated
Oppenheimer
Outperform
$4
Jun-13-19 Reiterated
H.C. Wainwright
Buy
$22 → $6
Jun-13-19 Downgrade
Ladenburg Thalmann
Buy → Neutral
$21 → $3
Jun-13-19 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Aug-13-18 Resumed
ROTH Capital
Neutral
$12
Jan-03-18 Initiated
Ladenburg Thalmann
Buy
$35
Sep-27-17 Resumed
ROTH Capital
Buy
$40
Sep-22-17 Initiated
Jefferies
Buy
$20
Sep-11-17 Initiated
JMP Securities
Mkt Outperform
$20
Show Previous Ratings
Sep-08-24 06:45AM
Sep-06-24 04:05PM
Sep-03-24 04:05PM
Sep-01-24 10:26PM
Aug-29-24 08:41PM
04:05PM
Loading…
Aug-16-24 04:05PM
Aug-15-24 08:05AM
Aug-12-24 04:05PM
Jun-29-24 08:35PM
06:30PM
Jun-28-24 08:50AM
Jun-26-24 07:41AM
06:30AM
Jun-25-24 08:05PM
Jun-19-24 09:00AM
06:00AM
Loading…
Jun-11-24 06:00AM
May-29-24 08:05AM
May-21-24 08:20AM
May-19-24 12:15PM
May-16-24 04:05PM
May-09-24 10:55PM
04:05PM
May-07-24 04:05PM
(Business Wire) +6.26%
-5.13%
Apr-08-24 08:05AM
Mar-22-24 04:05PM
Mar-07-24 10:54PM
04:05PM
Mar-06-24 04:05PM
Feb-02-24 08:05AM
Jan-31-24 08:05AM
03:01PM
Loading…
Dec-30-23 03:01PM
Dec-21-23 08:05AM
Dec-20-23 08:05AM
Dec-15-23 04:05PM
Nov-21-23 08:05AM
Nov-09-23 04:05PM
Nov-08-23 04:05PM
Oct-06-23 04:05PM
Sep-27-23 07:29PM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-05-23 04:05PM
Aug-10-23 04:05PM
Aug-04-23 04:05PM
Jul-13-23 07:00AM
Jun-26-23 04:05PM
08:05AM
Jun-02-23 08:05AM
May-28-23 08:26AM
May-16-23 12:32PM
May-15-23 08:05AM
May-05-23 04:05PM
Apr-03-23 07:33AM
Mar-31-23 04:05PM
Mar-30-23 04:05PM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 04:05PM
07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 04:05PM
06:43AM
Feb-27-23 06:50AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
06:24AM
Feb-14-23 08:05AM
06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 06:14AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 03:47PM
07:00AM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
Jan-24-23 06:48AM
Jan-23-23 06:58AM
Jan-20-23 08:05AM
06:55AM
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Pauls Matthew CHIEF EXECUTIVE OFFICER Dec 28 '23 Sale 4.71 84,000 395,900 1,302,674 Dec 29 04:35 PM Lowrance David L CHIEF FINANCIAL OFFICER Dec 28 '23 Sale 4.71 10,000 47,131 342,355 Dec 29 04:34 PM Elam Nevan C Director Dec 28 '23 Option Exercise 1.30 53,758 69,722 116,343 Dec 29 04:33 PM Elam Nevan C Director Dec 28 '23 Sale 4.71 93,843 442,291 22,500 Dec 29 04:33 PM Hawkins Richard J Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 12,741 Dec 12 06:09 PM Elam Nevan C Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 40,085 Dec 12 06:08 PM
Index -
P/E -
EPS (ttm) -0.61
Insider Own 8.38%
Shs Outstand 64.39M
Perf Week -1.82%
Market Cap 10.76M
Forward P/E -
EPS next Y -0.09
Insider Trans -26.51%
Shs Float 59.08M
Perf Month -9.78%
Income -39.11M
PEG -
EPS next Q -0.11
Inst Own 35.46%
Short Float 3.27%
Perf Quarter -35.13%
Sales 0.01M
P/S 1076.17
EPS this Y 12.93%
Inst Trans -1.73%
Short Ratio 0.52
Perf Half Y -94.20%
Book/sh 0.31
P/B 0.54
EPS next Y 82.18%
ROA -90.71%
Short Interest 1.93M
Perf Year -87.99%
Cash/sh 0.35
P/C 0.48
EPS next 5Y -
ROE -104.49%
52W Range 0.16 - 3.53
Perf YTD -92.93%
Dividend Est. -
P/FCF -
EPS past 5Y 13.11%
ROI -194.96%
52W High -95.27%
Beta 2.05
Dividend TTM -
Quick Ratio 5.48
Sales past 5Y -53.76%
Gross Margin -3102.77%
52W Low 7.68%
ATR (14) 0.01
Dividend Ex-Date -
Current Ratio 5.48
EPS Y/Y TTM 7.48%
Oper. Margin -408772.17%
RSI (14) 42.64
Volatility 8.18% 7.40%
Employees 35
Debt/Eq 0.02
Sales Y/Y TTM -86.67%
Profit Margin -391135.91%
Recom 3.00
Target Price 0.50
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q -21.87%
Payout -
Rel Volume 0.09
Prev Close 0.17
Sales Surprise -
EPS Surprise 7.46%
Sales Q/Q -
Earnings Aug 01
Avg Volume 3.71M
Price 0.17
SMA20 -1.70%
SMA50 -19.21%
SMA200 -88.79%
Trades
Volume 225,139
Change -1.82%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-26-24 Downgrade
TD Cowen
Buy → Hold
Dec-22-23 Initiated
CapitalOne
Overweight
$12
Nov-12-21 Upgrade
Jefferies
Hold → Buy
$3 → $4
Nov-14-19 Initiated
ROTH Capital
Buy
$12
Aug-05-19 Downgrade
SunTrust
Buy → Hold
$23 → $5
Aug-05-19 Downgrade
Piper Jaffray
Overweight → Neutral
$20 → $6
Aug-05-19 Downgrade
Jefferies
Buy → Hold
Apr-12-19 Initiated
Piper Jaffray
Overweight
$20
Dec-18-18 Initiated
H.C. Wainwright
Buy
$24
Jul-26-16 Initiated
SunTrust
Buy
Mar-17-15 Reiterated
Stifel
Buy
$13 → $14
Show Previous Ratings
Jul-25-24 09:00AM
Jul-22-24 07:00AM
Jun-26-24 07:41AM
Jun-25-24 07:37AM
Jun-04-24 07:00AM
04:01PM
Loading…
May-29-24 04:01PM
May-28-24 04:05AM
May-09-24 10:58PM
07:19PM
(Associated Press Finance)
May-08-24 07:42AM
May-07-24 05:21AM
May-06-24 03:53PM
12:45PM
08:40AM
07:52AM
07:28AM
Loading…
07:28AM
06:00AM
Apr-25-24 07:00AM
Mar-28-24 10:12AM
02:10AM
(Thomson Reuters StreetEvents)
Mar-27-24 11:53AM
10:31AM
07:14AM
(Associated Press Finance)
07:00AM
Mar-21-24 08:50AM
Mar-13-24 07:00AM
Feb-26-24 07:00AM
Feb-12-24 07:00AM
Jan-04-24 07:00AM
Jan-03-24 07:00AM
12:00PM
Loading…
Dec-10-23 12:00PM
Nov-09-23 07:00AM
Nov-05-23 08:51AM
Nov-04-23 01:48AM
(Thomson Reuters StreetEvents)
Nov-03-23 10:33AM
07:07AM
(Associated Press Finance)
07:00AM
Oct-23-23 08:30AM
Oct-20-23 07:00AM
Sep-06-23 07:00AM
Sep-05-23 07:00AM
Aug-17-23 07:00AM
Aug-02-23 07:17AM
(Associated Press Finance)
07:00AM
Jul-19-23 07:00AM
Jul-13-23 09:29AM
Jun-26-23 08:00AM
Jun-15-23 08:00AM
Jun-12-23 11:13AM
May-31-23 07:00AM
May-16-23 10:37AM
May-03-23 10:17PM
(Thomson Reuters StreetEvents)
+7.35%
07:23AM
07:00AM
Apr-26-23 07:00AM
Apr-19-23 10:20AM
Apr-05-23 01:45PM
Mar-31-23 04:30AM
Mar-29-23 07:00AM
Mar-21-23 06:23AM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 07:00AM
06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 07:00AM
06:01AM
06:01AM
Feb-28-23 06:43AM
Feb-27-23 06:50AM
Feb-24-23 07:17AM
07:17AM
Feb-16-23 08:00AM
Feb-15-23 08:00AM
Feb-14-23 06:23AM
Feb-06-23 07:00AM
Jan-22-23 07:30AM
07:24AM
Dec-30-22 07:17AM
Dec-28-22 06:58AM
Dec-26-22 07:14AM
Dec-19-22 09:40AM
Dec-12-22 07:00AM
Dec-02-22 01:18PM
09:40AM
Nov-23-22 09:55AM
Nov-16-22 09:40AM
Nov-12-22 07:14AM
Nov-10-22 09:12AM
(Simply Wall St.) +19.48%
Nov-09-22 07:00AM
Nov-08-22 04:05PM
Nov-03-22 09:00AM
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Invus Public Equities, L.P. 10% Owner Aug 08 '24 Sale 0.19 260,873 50,009 6,317,565 Aug 09 04:30 PM Invus Public Equities, L.P. 10% Owner Aug 07 '24 Sale 0.18 61,488 11,197 6,578,438 Aug 09 04:30 PM Invus Public Equities, L.P. 10% Owner Aug 05 '24 Sale 0.19 164,523 30,996 6,695,658 Aug 07 04:30 PM Invus Public Equities, L.P. 10% Owner Aug 06 '24 Sale 0.18 55,732 10,188 6,639,926 Aug 07 04:30 PM Invus Public Equities, L.P. 10% Owner Aug 02 '24 Sale 0.20 286,200 57,354 6,860,181 Aug 05 04:53 PM Invus Public Equities, L.P. 10% Owner Aug 01 '24 Sale 0.22 63,564 13,743 7,146,381 Aug 05 04:53 PM Invus Public Equities, L.P. 10% Owner Jul 30 '24 Sale 0.22 756,835 167,185 7,209,945 Jul 30 05:16 PM Invus Public Equities, L.P. 10% Owner Jul 29 '24 Sale 0.24 363,949 85,637 7,966,780 Jul 30 05:16 PM Invus Public Equities, L.P. 10% Owner Jul 26 '24 Sale 0.24 258,335 62,440 8,330,729 Jul 30 05:16 PM Rock Edwin Chief Medical Officer Jun 20 '24 Buy 0.25 190,000 48,108 565,403 Jun 24 04:29 PM Rock Edwin Chief Medical Officer Jun 21 '24 Buy 0.27 115,000 30,716 680,403 Jun 24 04:29 PM Hahn Brian M. SVP Finance, CFO Jun 18 '24 Buy 0.25 17,500 4,335 70,643 Jun 20 04:15 PM Rock Edwin Chief Medical Officer Sep 21 '23 Buy 1.38 35,000 48,300 345,000 Sep 25 04:21 PM Rock Edwin Chief Medical Officer Sep 22 '23 Buy 1.38 30,403 41,956 375,403 Sep 25 04:21 PM
Index RUT
P/E -
EPS (ttm) -1.08
Insider Own 24.92%
Shs Outstand 52.28M
Perf Week 12.93%
Market Cap 4.67B
Forward P/E -
EPS next Y -2.28
Insider Trans -5.58%
Shs Float 40.36M
Perf Month 30.30%
Income -53.89M
PEG -
EPS next Q -0.33
Inst Own 81.58%
Short Float 12.54%
Perf Quarter 54.73%
Sales 144.75M
P/S 32.25
EPS this Y 3.98%
Inst Trans 15.14%
Short Ratio 11.14
Perf Half Y 20.54%
Book/sh 9.08
P/B 9.56
EPS next Y -61.66%
ROA -7.94%
Short Interest 5.06M
Perf Year 151.62%
Cash/sh 9.61
P/C 9.03
EPS next 5Y -
ROE -13.80%
52W Range 30.88 - 86.11
Perf YTD 56.46%
Dividend Est. -
P/FCF -
EPS past 5Y -29.89%
ROI -10.07%
52W High 0.84%
Beta 0.24
Dividend TTM -
Quick Ratio 6.01
Sales past 5Y 0.00%
Gross Margin 97.77%
52W Low 181.20%
ATR (14) 3.47
Dividend Ex-Date -
Current Ratio 6.01
EPS Y/Y TTM 73.62%
Oper. Margin -55.73%
RSI (14) 82.05
Volatility 4.21% 4.65%
Employees 130
Debt/Eq 0.15
Sales Y/Y TTM 349.32%
Profit Margin -37.23%
Recom 1.12
Target Price 81.64
Option/Short Yes / Yes
LT Debt/Eq 0.10
EPS Q/Q -2.50%
Payout -
Rel Volume 1.53
Prev Close 85.43
Sales Surprise 24.27%
EPS Surprise 1.72%
Sales Q/Q 91.47%
Earnings Aug 08 AMC
Avg Volume 454.23K
Price 86.83
SMA20 19.49%
SMA50 32.22%
SMA200 44.94%
Trades
Volume 454,310
Change 1.64%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-03-24 Initiated
Cantor Fitzgerald
Overweight
May-31-24 Initiated
Piper Sandler
Overweight
$70
Mar-07-24 Initiated
Morgan Stanley
Overweight
$81
Jan-04-24 Reiterated
Needham
Buy
$65 → $71
Dec-19-23 Initiated
Scotiabank
Sector Outperform
$66
Oct-30-23 Initiated
TD Cowen
Outperform
Oct-17-23 Initiated
UBS
Buy
$52
May-18-23 Initiated
Truist
Buy
$60
Apr-14-23 Initiated
Robert W. Baird
Outperform
$39
Mar-14-23 Initiated
Stifel
Buy
$43
Feb-13-23 Initiated
H.C. Wainwright
Buy
$42
Dec-13-22 Resumed
BofA Securities
Buy
$29 → $37
Oct-31-22 Initiated
Guggenheim
Buy
$36
Oct-27-22 Initiated
Needham
Buy
$31
Jul-20-22 Initiated
Canaccord Genuity
Buy
$32
Mar-01-22 Initiated
SVB Leerink
Outperform
$47
Mar-01-22 Initiated
BofA Securities
Buy
$24
Show Previous Ratings
Aug-08-24 05:25PM
04:00PM
Aug-02-24 06:53AM
Jul-04-24 02:13PM
Jun-29-24 03:08AM
04:42PM
Loading…
Jun-21-24 04:42PM
(Investor's Business Daily)
May-27-24 12:32PM
May-25-24 03:11AM
May-17-24 08:06AM
May-15-24 07:21AM
May-14-24 08:00AM
May-10-24 01:13PM
04:21AM
May-09-24 10:57PM
05:10PM
04:05PM
Loading…
04:05PM
04:05PM
04:00PM
06:49AM
May-07-24 04:00PM
May-03-24 05:57PM
Apr-23-24 11:26AM
Apr-04-24 04:00PM
08:40AM
Mar-29-24 02:57PM
Mar-28-24 08:13AM
Mar-27-24 01:50AM
Mar-20-24 04:00PM
Feb-29-24 04:00PM
Feb-28-24 07:30PM
04:00PM
Loading…
04:00PM
Feb-15-24 11:57AM
Jan-16-24 01:51PM
Dec-22-23 01:30AM
Dec-15-23 05:04PM
Dec-08-23 04:00PM
Nov-30-23 09:37PM
Nov-21-23 08:00AM
(Investor's Business Daily)
Nov-16-23 10:10AM
Nov-15-23 04:05PM
(Investor's Business Daily) +5.31%
09:47AM
09:22AM
07:16AM
06:00AM
06:00AM
Nov-13-23 04:47PM
04:00PM
Nov-09-23 11:14AM
08:30AM
Nov-02-23 09:40AM
09:00AM
Oct-26-23 04:00PM
Oct-23-23 02:50AM
Oct-17-23 09:40AM
Sep-29-23 12:43PM
Sep-04-23 09:55AM
Sep-01-23 09:18AM
Aug-17-23 09:55AM
Aug-16-23 01:21PM
Aug-14-23 04:00PM
Jul-31-23 07:13AM
Jul-25-23 02:37AM
Jun-26-23 12:48PM
Jun-22-23 11:04AM
Jun-21-23 10:38AM
Jun-20-23 04:05PM
(Investor's Business Daily) -7.18%
Jun-19-23 07:46PM
May-11-23 10:45AM
May-10-23 06:11AM
May-08-23 05:15PM
04:00PM
May-04-23 04:59AM
May-03-23 06:44AM
Apr-28-23 03:34PM
Apr-25-23 12:00PM
Apr-21-23 12:00PM
Apr-13-23 04:01PM
Apr-11-23 10:00AM
Apr-05-23 09:55AM
Apr-04-23 12:20PM
Apr-03-23 08:34AM
Mar-29-23 05:25PM
04:01PM
Mar-16-23 12:18PM
Feb-21-23 04:00PM
Feb-02-23 04:00PM
Jan-30-23 09:00AM
Jan-04-23 11:45AM
Dec-14-22 10:24AM
Dec-12-22 10:55AM
Dec-09-22 04:08PM
(Investor's Business Daily) +29.24%
09:54AM
09:42AM
08:46AM
08:17AM
08:17AM
08:15AM
Nov-30-22 11:08AM
Nov-14-22 04:00PM
01:13PM
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gilson Michelle CHIEF FINANCIAL OFFICER Sep 17 '24 Option Exercise 8.66 15,000 129,900 21,915 Sep 17 08:54 PM Gilson Michelle CHIEF FINANCIAL OFFICER Sep 17 '24 Sale 77.73 15,000 1,165,880 6,915 Sep 17 08:54 PM MICHELLE GILSON Officer Sep 17 '24 Proposed Sale 77.01 15,000 1,155,150 Sep 17 04:39 PM Patel Kavita Director Sep 10 '24 Option Exercise 6.66 1,500 9,990 1,500 Sep 12 06:27 PM Patel Kavita Director Sep 10 '24 Sale 74.41 1,500 111,615 0 Sep 12 06:27 PM Heery Christopher CHIEF MEDICAL OFFICER Sep 05 '24 Option Exercise 15.00 3,421 51,315 12,699 Sep 06 05:48 PM Heery Christopher CHIEF MEDICAL OFFICER Sep 05 '24 Sale 70.02 3,421 239,526 9,278 Sep 06 05:48 PM Heery Christopher CHIEF MEDICAL OFFICER Sep 03 '24 Option Exercise 13.27 27,451 364,232 36,729 Sep 03 09:33 PM Heery Christopher CHIEF MEDICAL OFFICER Sep 03 '24 Sale 67.03 27,451 1,840,053 9,278 Sep 03 09:33 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 26 '24 Option Exercise 15.00 21,684 325,260 30,962 Aug 28 04:54 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 26 '24 Sale 71.12 21,684 1,542,274 9,278 Aug 28 04:54 PM CHRISTOPHER HEERY Officer Aug 26 '24 Proposed Sale 69.38 48,907 3,393,168 Aug 26 04:24 PM Patel Kavita Director Aug 20 '24 Option Exercise 6.66 1,500 9,990 1,500 Aug 22 04:01 PM Patel Kavita Director Aug 20 '24 Sale 65.88 1,500 98,820 0 Aug 22 04:01 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 16 '24 Option Exercise 6.28 5,450 34,226 14,728 Aug 19 04:39 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 16 '24 Sale 65.05 5,450 354,526 9,278 Aug 19 04:39 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 01 '24 Option Exercise 10.94 20,000 218,764 29,278 Aug 02 04:02 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 01 '24 Sale 60.42 20,000 1,208,435 9,278 Aug 02 04:02 PM Patel Kavita Director Jul 30 '24 Option Exercise 6.66 1,500 9,990 1,500 Aug 01 05:24 PM Patel Kavita Director Jul 30 '24 Sale 61.97 1,500 92,949 0 Aug 01 05:24 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 16 '24 Option Exercise 6.28 10,901 68,458 20,179 Jul 18 06:44 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 16 '24 Sale 65.30 10,901 711,854 9,278 Jul 18 06:44 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 11 '24 Option Exercise 6.28 3,671 23,054 12,949 Jul 12 06:39 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 12 '24 Option Exercise 6.28 1,780 11,178 11,058 Jul 12 06:39 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 11 '24 Sale 60.01 3,671 220,302 9,278 Jul 12 06:39 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 12 '24 Sale 60.21 1,780 107,175 9,278 Jul 12 06:39 PM Patel Kavita Director Jul 09 '24 Option Exercise 6.66 1,500 9,990 1,500 Jul 11 04:04 PM Patel Kavita Director Jul 09 '24 Sale 56.63 1,500 84,947 0 Jul 11 04:04 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 01 '24 Option Exercise 11.93 20,000 238,646 29,278 Jul 03 04:05 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 01 '24 Sale 55.39 20,000 1,107,763 9,278 Jul 03 04:05 PM Patel Kavita Director Jun 27 '24 Option Exercise 6.66 10,000 66,600 10,000 Jun 28 04:08 PM Patel Kavita Director Jun 27 '24 Sale 54.27 10,000 542,656 0 Jun 28 04:08 PM Gilson Michelle CHIEF FINANCIAL OFFICER Jun 26 '24 Sale 53.70 12,877 691,519 6,915 Jun 28 04:06 PM Heery Christopher CHIEF MEDICAL OFFICER Jun 12 '24 Option Exercise 11.53 20,000 230,554 29,278 Jun 14 04:31 PM Heery Christopher CHIEF MEDICAL OFFICER Jun 12 '24 Sale 55.13 20,000 1,102,668 9,278 Jun 14 04:31 PM Gilson Michelle CHIEF FINANCIAL OFFICER May 23 '24 Option Exercise 0.00 22,428 0 31,913 May 24 08:16 PM Gilson Michelle CHIEF FINANCIAL OFFICER May 24 '24 Sale 50.71 12,121 614,656 19,792 May 24 08:16 PM Heery Christopher CHIEF MEDICAL OFFICER May 01 '24 Option Exercise 6.28 18,168 114,095 27,106 May 03 05:50 PM Heery Christopher CHIEF MEDICAL OFFICER May 01 '24 Sale 51.33 18,168 932,557 8,938 May 03 05:50 PM Ware Olivia C Director Apr 16 '24 Option Exercise 7.61 9,402 71,549 9,402 Apr 18 04:01 PM Ware Olivia C Director Apr 16 '24 Sale 55.55 9,402 522,260 0 Apr 18 04:01 PM Elghandour Rami SEE REMARKS Apr 01 '24 Sale 67.09 23,086 1,548,887 69,253 Apr 03 04:44 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 22 '24 Option Exercise 6.28 20,000 125,600 50,303 Mar 26 08:52 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 26 '24 Option Exercise 6.28 5,450 34,226 14,388 Mar 26 08:52 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 22 '24 Sale 70.18 41,365 2,903,066 8,938 Mar 26 08:52 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 26 '24 Sale 69.11 5,450 376,648 8,938 Mar 26 08:52 PM Carroll Jill Director Mar 21 '24 Sale 70.55 504,263 35,575,755 1,479,148 Mar 25 05:30 PM Gilson Michelle CHIEF FINANCIAL OFFICER Mar 18 '24 Sale 69.34 6,825 473,255 9,485 Mar 18 08:49 PM Ware Olivia C Director Mar 15 '24 Option Exercise 7.61 9,000 68,490 9,000 Mar 18 06:38 PM Ware Olivia C Director Mar 15 '24 Sale 70.40 9,000 633,582 0 Mar 18 06:38 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 09 '24 Sale 63.40 3,688 233,811 33,270 Feb 12 07:46 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 08 '24 Sale 62.29 3,456 215,290 36,958 Feb 12 07:46 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 12 '24 Sale 64.46 2,967 191,251 30,303 Feb 12 07:46 PM Elghandour Rami SEE REMARKS Feb 09 '24 Sale 63.40 13,886 880,340 103,508 Feb 12 07:43 PM Elghandour Rami SEE REMARKS Feb 08 '24 Sale 62.29 13,010 810,451 117,394 Feb 12 07:43 PM Elghandour Rami SEE REMARKS Feb 12 '24 Sale 64.46 11,169 719,948 92,339 Feb 12 07:43 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 07 '24 Option Exercise 0.00 22,555 0 40,414 Feb 09 04:08 PM Elghandour Rami SEE REMARKS Feb 07 '24 Option Exercise 0.00 70,211 0 130,404 Feb 09 04:05 PM Heery Christopher Chief Medical Officer Jan 04 '24 Sale 55.27 7,598 419,926 17,859 Jan 08 04:06 PM Gilson Michelle Chief Financial Officer Jan 04 '24 Sale 55.27 8,514 470,551 16,310 Jan 08 04:04 PM Elghandour Rami See Remarks Jan 04 '24 Sale 55.27 29,073 1,606,804 60,193 Jan 08 04:02 PM Heery Christopher Chief Medical Officer Jan 03 '24 Option Exercise 0.00 16,519 0 25,457 Jan 04 07:32 PM Elghandour Rami See Remarks Jan 03 '24 Option Exercise 0.00 53,097 0 89,266 Jan 04 07:29 PM Heery Christopher Chief Medical Officer Dec 18 '23 Option Exercise 6.28 120,000 753,600 127,795 Dec 19 04:43 PM Heery Christopher Chief Medical Officer Dec 18 '23 Sale 50.17 120,000 6,020,281 7,795 Dec 19 04:43 PM Carroll Jill Director Dec 14 '23 Sale 49.13 504,263 24,774,441 1,983,411 Dec 18 04:47 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite